| |
|
|
|
|
|
Lucentis® (ranibizumab injection) is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Status
In June 2006, the U.S. Food and Drug Administration (FDA) approved Lucentis for the treatment of neovascular wet AMD after a Priority Review (six-month).
The FDA approval of Lucentis is based on data from two large Phase III clinical trials (MARINA and ANCHOR) and one Phase IIIb study (PIER). In the Phase III studies:
Nearly all patients (approximately 95 percent) treated with Lucentis (0.5 mg) maintained (defined as the loss of less than 15 letters in visual ac
|
Company:
Date:
April 16, 2009
|
|
|
|
|